生物技術領域的授權協議（2021-2026 年）

利用 2,157 筆真實交易的訊息，讓我們加深對生物技術領域授權協議的結構、評估和談判機制的理解。

《生物技術領域的許可協議》提供了有關 2,157 項涉及生物技術公司的許可協議的全面資訊。

許可對於生物技術公司的經營模式至關重要，它使生物技術公司能夠將資產和技術貨幣化，利用開發和商業化能力，獲得新的創新來源，並分擔推進產品開發所需的投資和風險。

本報告探討了生物技術領域的授權交易結構、哪些公司最活躍、合作活動集中在哪些領域，以及可以從揭露的財務條款和公開的合約文件中檢驗什麼。

這份報告不僅僅是列出交易；它為希望了解許可內容、參與者、資訊來源和責任如何分配、金錢考量如何構建以及類似協議實際如何談判的團隊提供了可操作的信息和基準資源。

本報告旨在為參與評估、開發或談判生物技術領域許可交易的業務發展、許可、研究和評估、公司策略、法律、合作夥伴關係管理以及高階主管團隊提供參考。

了解生物技術許可的現狀

本報告分析了2021年至2026年期間簽訂的授權協議的現狀，內容包括：

• 授權協議簽訂情況的年度趨勢
• 合作關係發展階段
• 產業部門
• 治療區域
• 技術類型
• 最活躍的許可合約簽署公司
• 根據披露金額達成的主要許可協議
• 簽署許可協議的策略原因
• 生物技術領域授權策略的演變
• 這有助於我們清楚地了解許可活動集中在哪些領域，以及哪些技術、治療領域、開發階段和公司在合作方面吸引了人們的興趣。
• 了解生物技術領域授權協議的結構
• 授權協議需要仔細分配智慧財產權、開發責任、商業性權利、經濟條款以及對資產和技術的未來控制權。

本報告提供以下信息，幫助使用者探索以下領域：

• 授予的權利和保留的權利
• 獨家許可和非獨家許可
• 地理和區域權利
• 應用領域的限制
• 智慧財產權的所有權和管理權
• 開發方面的職責
• 監管責任
• 製造和供應安排
• 商業化方面的權利義務
• 轉讓許可權
• 管治與決策
• 關於開發和商業化的實質審查
• 合約期限和終止條款
• 如已揭露，財務狀況如下：
• 這些案例研究將為準備進行資產和技術許可談判的生物技術公司提供寶貴的參考資料。
• 許可協議財務條款的基準
• 財務結構是生物技術領域授權核准中極為重要的因素。

本報告提供與個別交易相關的已披露財務信息，使用戶能夠調查以下要素：

• 預付款
• 發展里程碑
• 監管里程碑
• 商業化里程碑
• 特許權使用費協議
• 股票投資
• 研發經費
• 已揭露的其他財務承諾
• 主要許可協議按披露的合約價值進行排名，使用戶能夠識別關鍵領先並研究其底層結構。
• 這些資訊有助於用戶將提案的交易置於與類似實際交易的比較背景下，從而為內部評估、交易準備和談判奠定更堅實的基礎。
• 尋找有前景的授權合作夥伴
• 對於考慮許可資產、平台或技術的生技公司而言，了解哪些組織先前處理過相關交易是確定潛在合作夥伴的關鍵起點。

本報告概述了排名前 25 位最活躍的授權公司，並提供詳細的交易歷史記錄，以幫助用戶在以下領域找到他們特別感興趣的公司：

• 治療區域
• 技術類型
• 資產類別
• 發展階段
• 許可協議的結構
• 這有助於進行有針對性的業務發展、研究和評估、競爭分析，並識別積極主動地引入外部創新的組織。
• 從實際授權協議中吸取經驗
• 本報告在有相關許可協議文件的情況下，提供查閱該文件的途徑。

這些合約揭示了許多僅憑交易頭條新聞無法獲得的信息，並允許用戶檢驗每家公司如何談判和記錄如下條款。

• 許可範圍
• 獨家版權
• 目標區域和領域
• 智慧財產
• 發展義務
• 重新授權
• 生產和銷售權
• 預付款和里程碑付款
• 特許權使用費規定
• 合約終止和權利返還條款
• 對於準備進行許可交易的生物技術公司而言，獲取實際合約措辭可以深入了解類似條款在實踐中的結構。
• 綜合生物技術授權合約目錄
• 本報告包含 2,157 項生物技術授權協議的綜合目錄，使用戶能夠找到與其資產、技術和合作目標相關的交易。

在以下條件下可以查看交易記錄：

• 公司
• 治療區域
• 技術類型
• 合約揭露狀態
• 每筆交易都與其底層交易記錄相關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
• 誰該使用這份報告？
• 業務拓展與授權團隊
• 在製定引入授權或對外授權策略時，要確定類似的交易、潛在的合作夥伴以及相關的合約結構。
• 尋求合作夥伴的生技公司
• 找出對類似資產、技術、治療領域和發展階段表現出明確興趣的組織。
• 研究與評估團隊
• 我們調查跨技術、治療領域和公司的許可活動，以確定外部創新的優先事項。
• 企業策略與投資組合策略團隊
• 本文探討了生技公司如何利用授權來實現創新貨幣化、取得能力和推動研發專案。
• 法律及交易團隊
• 我們會仔細審查實際的合約架構和公開的合約條款，並協助進行合約起草、談判和實質審查。
• 合作夥伴關係管理團隊
• 了解類似授權協議中權利、責任、管治和持續義務的結構。
• 競爭情報與市場情報團隊
• 我們按公司、技術、治療領域和開發階段追蹤許可活動，以確定夥伴關係重點的變化。
• 我們將整體市場資訊轉化為針對每家公司的具體洞察。
• 符合資格的客戶除了收到報告外，還將收到 Current Partnering 提供的定製版「高階主管合作夥伴簡報」。
• 本次簡報將解釋生物技術許可的基本訊息，並根據您的特定資產、技術和合作目標量身定做。
• 如有需要，我們可以提供相關的類似交易、有前景的許可合作夥伴、競爭對手的活動、交易結構、財務基準、合約見解以及其他專門為您情況選擇的資訊。
• 請索取樣本或聯絡 Current Partnering 討論本報告的內容以及我們是否可以為貴公司提供客製化分析。

目錄

執行摘要

第1章：引言

第2章：授權協議的發展趨勢

• 介紹
• 許可協議的定義
• 授權協議的趨勢
• 簽訂許可合作協議的原因
• 授權協議的未來

第3章 授權合約結構概述

• 介紹
• 許可協議的結構

第4章 主要授權協議

• 介紹
• 最高許可合約金額

第5章：最活躍的25家授權交易商

• 介紹
• 前 25 名最活躍的授權交易商

第6章：許可協議（包括協議清單）

• 介紹
• 授權協議
• 特價優惠列表
• 交易目錄 - 公司 AZ 的授權交易
• 交易目錄 - 按治療領域分類的授權交易
• 交易目錄 - 按技術類型分類的授權交易
• 關於 Biopharma Research Ltd.
• Current Partnering
• 目前合約
• 最新報告標題

Understand how biotechnology licensing deals are structured, valued and negotiated using intelligence from 2,157 real-world transactions.

Licensing Deals in Biotechnology provides comprehensive intelligence on 2,157 licensing deals involving biotechnology companies.

Licensing is central to the biotechnology business model, enabling companies to monetize assets and technologies, access development and commercial capabilities, secure new sources of innovation and share the investment and risk required to advance products through development.

The report examines how biotechnology licensing transactions are structured, which companies are most active, where partnering activity is concentrated and what can be learned from disclosed financial terms and publicly available contract documents.

Rather than simply identifying transactions, the report provides a practical intelligence and benchmarking resource for teams seeking to understand what is being licensed, who is partnering, how rights and responsibilities are allocated, how financial consideration is structured and how comparable agreements have been negotiated in practice.

It is designed for business development, licensing, search and evaluation, corporate strategy, legal, alliance management and senior management teams involved in evaluating, structuring or negotiating biotechnology licensing transactions.

Understand the biotechnology licensing landscape

The report analyzes licensing dealmaking from 2021 to 2026, including:

• Trends in licensing dealmaking by year
• Phase of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active licensing dealmakers
• Leading licensing deals by disclosed value
• Strategic reasons for entering licensing agreements
• How biotechnology licensing strategies are evolving
• This provides a clear view of where licensing activity is concentrated and which technologies, therapeutic areas, development stages and companies are attracting partnering interest.
• Understand how biotechnology licensing agreements are structured
• Licensing agreements require careful allocation of intellectual property rights, development responsibilities, commercial rights, economics and future control of an asset or technology.

The report provides intelligence to help users examine areas including:

• Rights granted and retained
• Exclusive and non-exclusive licenses
• Geographic and territorial rights
• Field-of-use restrictions
• Intellectual property ownership and control
• Development responsibilities
• Regulatory responsibilities
• Manufacturing and supply arrangements
• Commercialization rights and obligations
• Sublicensing rights
• Governance and decision-making
• Development and commercialization diligence
• Term and termination provisions
• Financial terms where disclosed
• These real-world examples provide valuable reference points for biotechnology companies preparing assets or technologies for licensing discussions.
• Benchmark licensing deal financials
• Financial structure is a critical element of biotechnology licensing.

The report provides access to disclosed financial information associated with individual transactions, enabling users to investigate elements including:

• Upfront payments
• Development milestones
• Regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity investments
• Research and development funding
• Other financial commitments where disclosed
• Leading licensing deals are also ranked by disclosed deal value, enabling users to identify significant precedent transactions and investigate their underlying structures.
• This intelligence can help users place proposed transactions into the context of comparable real-world deals and establish stronger evidence for internal valuation, deal preparation and negotiation.
• Identify prospective licensing partners
• For biotechnology companies seeking to out-license an asset, platform or technology, understanding which organizations have previously entered relevant transactions can provide an important starting point for partner identification.

The report profiles the Top 25 most active licensing dealmakers and provides extensive transaction histories that can help users identify companies with demonstrated interest in particular:

• Therapeutic areas
• Technology types
• Asset classes
• Development stages
• Licensing structures
• This supports targeted business development, search and evaluation, competitor analysis and the identification of organizations with an established appetite for external innovation.
• Learn from real-world licensing contracts
• Where publicly available, the report provides access to underlying licensing contract documents.

These agreements can reveal considerably more than headline deal announcements, allowing users to examine how companies have negotiated and documented provisions including:

• Scope of license
• Exclusivity
• Territory and field
• Intellectual property rights
• Development obligations
• Sublicensing
• Manufacturing and commercialization rights
• Upfront and milestone payments
• Royalty provisions
• Termination and reversion rights
• For biotechnology companies preparing for a licensing transaction, access to real agreement language provides valuable insight into how comparable terms have been structured in practice.
• Comprehensive biotechnology licensing deal directory
• The report includes a comprehensive directory of 2,157 biotechnology licensing deals, enabling users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable transactions, prospective partners and relevant structures when preparing in-licensing or out-licensing strategies.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable assets, technologies, therapeutic areas and development stages.
• Search and Evaluation teams
• Investigate licensing activity across technologies, therapeutic areas and companies to understand external innovation priorities.
• Corporate and Portfolio Strategy teams
• Understand how biotechnology companies use licensing to monetize innovation, access capabilities and advance development programs.
• Legal and Transaction teams
• Review real agreement structures and publicly available contract language to support drafting, negotiation and due diligence.
• Alliance Management teams
• Understand how rights, responsibilities, governance and continuing obligations have been structured across comparable licensing relationships.
• Competitive and Market Intelligence teams
• Track licensing activity by company, technology, therapy area and development phase to identify changing partnering priorities.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying biotechnology licensing intelligence to the customer's own assets, technologies and partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective licensing partners, competitor activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals
  • 2.3.1. Licensing dealmaking by year
  • 2.3.2. Licensing dealmaking by phase of development
  • 2.3.3. Licensing dealmaking by industry sector
  • 2.3.4. Licensing dealmaking by therapy area
  • 2.3.5. Licensing dealmaking by technology type
  • 2.3.6. Licensing dealmaking by most active company
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements
• Figure 3: Licensing deals signed at each phase of development
• Figure 4: Licensing deals by industry sector
• Figure 5: Licensing deals by therapy area
• Figure 6: Licensing deals by technology type
• Figure 7: Top 25 most active licensing dealmakers
• Figure 8: Top licensing deals by value
• Figure 9: Most active licensing dealmakers